Skip to main content
رجوع
Watch Compare

CASI Pharmaceuticals, Inc.

جودة البيانات: 100%
CASIF
OTC Manufacturing Chemicals
KWD 0.13
▲ KWD 0.01 (7.08%)
6 months return
—
Momentum
Neutral
ROE
-301.80%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-15.77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-301.80%
أقل من متوسط القطاع (-54.47%)
ROIC-82.63%
Net Margin-137.57%
Op. Margin-138.84%

الأمان

Debt / Equity
10.21
أعلى من متوسط القطاع (0.30)
Current Ratio1.09
Interest CoverageN/A

التقييم

PE (TTM)
-0.06
أعلى من متوسط القطاع (-1.50)
P/B Ratio1.35
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Debt/Equity of 10.21 — high leverage
Negative free cash flow of -29.45 M
Capital efficient — spends only 0.78% of revenue on capex

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

محلل 1
Hold
+2976.9%
upside to target
الحالي
KWD 0.13
Consensus Target
KWD 4.00
KWD 4.00
أدنى
KWD 4.00
أعلى
التوقعات
ربحية السهم المستقبلية
-KWD 1.41
الإيرادات المقدّرة
0.0

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.36 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q1 '26
Reported -KWD 0.69 -KWD 0.86 -KWD 0.67 —
Estimate -KWD 0.61 -KWD 0.47 -KWD 0.40 -KWD 0.36
المفاجأة -13.11% -82.98% -67.50% —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -15.77% Revenue Growth (3Y) -18.64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -301.80% · Net Margin: -137.57%
Revenue (TTM) 28.54 M Net Income (TTM) -39.26 M
ROE -301.80% ROA -60.89%
Gross Margin 39.06% Operating Margin -138.84%
Net Margin -137.57% Free Cash Flow (TTM) -29.45 M
ROIC -82.63% FCF Growth (3Y) N/A

Safety

D/E: 10.21 · Current: 1.09
Debt / Equity 10.21 Current Ratio 1.09
Interest Coverage N/A Asset Turnover 0.44
Working Capital 3.12 M Tangible Book Value 1.61 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.06 · EV/EBITDA: N/A
P/E Ratio -0.06 Forward P/E N/A
P/B Ratio 1.35 P/S Ratio 0.09
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1175.61%
Market Cap 2.50 M Enterprise Value 7.93 M

Per Share

EPS: -2.56 · FCF/Share: -1.43
EPS (Diluted TTM) -2.56 Revenue / Share 1.39
FCF / Share -1.43 OCF / Share -1.42
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 75.01% · CapEx/Rev: 0.78%
CapEx / Revenue 0.78% FCF Conversion 75.01%
SBC-Adj. FCF -30.75 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 28.54 M 33.88 M 43.11 M
Net Income -39.26 M -26.96 M -41.01 M
EPS (Diluted) -2.56 -2.02 -3.01
Gross Profit 11.15 M 20.05 M 27.28 M
Operating Income -39.62 M -25.08 M -34.03 M
EBITDA — — —
R&D Expenses 8.92 M — —
SG&A Expenses — — —
D&A 1.30 M 2.50 M 1.20 M
Interest Expense — 614,000.0 0.0
Income Tax 0.0 -81,000.0 1.98 M

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 53.67 M 75.27 M 96.23 M
Total Liabilities 51.82 M 51.10 M 29.30 M
Shareholders' Equity 1.85 M 24.17 M 44.57 M
Total Debt 18.90 M 18.90 M —
Cash & Equivalents 13.47 M 17.08 M 47.11 M
Current Assets 39.58 M 59.34 M 73.42 M
Current Liabilities 36.45 M 16.73 M 17.01 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -0.1 -1.5
P/B 1.4 1.6
ROE % -301.8 -54.5
Net Margin % -137.6 -41.5
Rev Growth 5Y % — 1.9
D/E 10.2 0.3